7 unknown, 4 recruiting, 2 completed, 1 not yet recruiting. 15 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Unknown 7, Recruiting 4, Completed 2, Not yet recruiting 1, Suspended 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow Bevacizumab: new trials by email Literature Review of Bevacizumab trials Research Report on Bevacizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial Transarterial Chemoembolization (TACE), Hepatic Arterial Infusion Chemotherapy (HAIC, FOLFOX), Adebrelimab - Adebrelimab (SHR-1316), Bevacizumab | Phase 2 | Not yet recruiting | Third Affiliated Hospital, Sun Yat-Sen University | 38 | 2026-04-10 | 2026-04-28 |
| QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT Iparomlimab and Tuvonralimab Injection (QL1706), Bevacizumab, Hepatic Arterial Infusion Chemotherapy with Raltitrexed and Oxaliplatin (RALOX-HAIC) - Hepatecellular Carcinoma, RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin | Phase 2 | Recruiting | Nanfang Hospital, Southern Medical University | 38 | 2025-12-25 | 2026-01-13 |
| Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer Nivolumab, Bevacizumab, BMS-986340 - Microsatellite-stable Colorectal Cancer, Standard of Care | Phase 2 | Suspended | M.D. Anderson Cancer Center | 7 | 2025-08-15 | 2026-11-02 |
| Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC Trifluridine/tipiracil (TAS-102) plus bevacizumab - Colo-rectal Cancer, Third-line and Beyond Therapy | Phase 2 | Recruiting | Ruijin Hospital | 50 | 2025-08-01 | 2025-07-25 |
| Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer Befotertinib combined Bevacizumab, Befotertinib combined platinum-based double chemotherapy - EGFR, Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Peng Zhang | 60 | 2024-11-07 | 2025-01-06 |
| Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer Eribulin, Bevacizumab - Breast Neoplasms, Neoplasm Metastasis | Phase 2 | Unknown | Wang Jiayu | 60 | 2024-08-01 | 2024-08-06 |
| Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma TACE with adebrelimab and bevacizumab - Adebrelimab, Hepatocellular Carcinoma | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 71 | 2023-11-15 | 2024-02-28 |
| XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine - Tislelizumab, Bevacizumab | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 52 | 2023-07-07 | 2023-08-01 |
| Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases Serplulimab combined with bevacizumab and first-line chemotherapy - Non-small Cell Lung Cancer Stage II, Bevacizumab | Phase 2 / Phase 3 | Completed | Sun Yat-sen University | 40 | 2023-05-14 | 2024-11-13 |
| Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy Bevacizumab+mFOLFOX6 - Neoadjuvant Treatment, Rectal Cancer | Phase 1 / Phase 2 | Unknown | Shanghai Minimally Invasive Surgery Center | 20 | 2022-11-01 | 2024-03-07 |
| Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer Albumin-bound paclitaxel and bevacizumab - Ovarian Carcinoma, Platinum-resistant Ovarian Cancer | Phase 2 | Unknown | Lei Li | 50 | 2022-03-27 | 2022-04-04 |
| Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation Bevacizumab, Icotinib - Carcinoma, Non-Small-Cell Lung, Bevacizumab | Phase 2 | Completed | Tianjin Medical University Cancer Institute and Hospital | 35 | 2022-01-30 | 2026-02-24 |
| HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama Hepatic arterial infusion chemotherapy, Bevacizumab, Toripalimab - Hepatocellular Carcinoma, Bevacizumab | Phase 2 | Unknown | Sun Yat-sen University | 30 | 2021-01-01 | 2020-11-13 |
| Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer Niraparib, Bevacizumab - Ovarian Neoplasms, Fallopian Tube Neoplasms | Phase 2 | Unknown | Xiaoxiang Chen | 32 | 2020-11-06 | 2020-11-10 |
| Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer sintilimab - Brain Metastases, Non Small Cell Lung Cancer | Phase 2 | Unknown | Sun Yat-sen University | 60 | 2019-04-29 | 2019-12-30 |
Carcinoma, Non-Small-Cell Lung (4) · Carcinoma, Hepatocellular (3) · Brain Neoplasms (2) · Ovarian Neoplasms (2) · Adnexal Diseases (1) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Ovarian Epithelial (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Fallopian Tube Neoplasms (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1)
Neoplasms (12) · Neoplasms by Site (12) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Bronchial Neoplasms (4) · Carcinoma, Bronchogenic (4) · Lung Diseases (4) · Lung Neoplasms (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4) · Adenocarcinoma (3) · Carcinoma (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3)
Bevacizumab (11) · trifluridine tipiracil drug combination (2) · Albumin-Bound Paclitaxel (1) · Folfox protocol (1) · Nivolumab (1) · Oxaliplatin (1) · Trifluridine (1) · eribulin (1) · icotinib (1) · niraparib (1) · raltitrexed (1) · sintilimab (1) · tipiracil (1) · toripalimab (1)
Sun Yat-sen University (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Lei Li (1) · M.D. Anderson Cancer Center (1) · Nanfang Hospital, Southern Medical University (1) · Peng Zhang (1) · Ruijin Hospital (1) · Shanghai Minimally Invasive Surgery Center (1) · The First Affiliated Hospital of Xiamen University (1) · Third Affiliated Hospital, Sun Yat-Sen University (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Wang Jiayu (1) · Xiaoxiang Chen (1)
China (12) · United States (1)
Fei Gao (1) · Feng Lin (1) · Feng Ye (1) · Jiafei Chen (1) · Jianbo Chen (1) · Jiayu Wang, doctor (1) · Jinzhang Chen, Study Director (1) · Kangshun Zhu, Professor (1) · Lei Li, M.D. (1) · Likun Chen, doctor (1) · Madhulika Eluri, MD (1) · Qinghe Cai (1) · Xiaoxiang Chen, MD,PhD (1) · Yongzhong Wang (1) · Zhanyu Pan (1)